Literature DB >> 2572874

Reversal of HIV-phenotype to fulminant replication on macrophages in perinatal transmission.

H Rübsamen-Waigmann, W R Willems, U Bertram, H von Briesen.   

Abstract

Mesh：

Year:  1989        PMID： 2572874     DOI： 10.1016/s0140-6736(89)91518-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.

Authors:  H Rübsamen-Waigmann; B Schröder; L Biesert; C D Bauermeister; H von Briesen; H Suhartono; F Zimmermann; H D Brede; A Regeniter; S Gerte
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.

Authors:  A R Bender; H von Briesen; J Kreuter; I B Duncan; H Rübsamen-Waigmann
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.

Authors:  S Kehlenbeck; U Betz; A Birkmann; B Fast; A H Göller; K Henninger; T Lowinger; D Marrero; A Paessens; D Paulsen; V Pevzner; R Schohe-Loop; H Tsujishita; R Welker; J Kreuter; H Rübsamen-Waigmann; F Dittmer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.

Authors:  M Groenink; R A Fouchier; R E de Goede; F de Wolf; R A Gruters; H T Cuypers; H G Huisman; M Tersmette
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Relevance of early detection of HIV type 1 SI/CXCR4-using viruses in vertically infected children.

Authors:  Cintia M Crudeli; Paula C Aulicino; Carlos A Rocco; Rosa Bologna; Andrea Mangano; Luisa Sen
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-02       Impact factor: 2.205

8.  Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.

Authors:  S C Wu; J L Spouge; S R Conley; W P Tsai; M J Merges; P L Nara
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting.

Authors:  V Schäfer; H von Briesen; R Andreesen; A M Steffan; C Royer; S Tröster; J Kreuter; H Rübsamen-Waigmann
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.